National 0Updated at 3:22 pm, August 30th, 2017 By: Michael Nedelman, CNN We Matched
(CNN) The US Food and Drug Administration approved a new leukemia treatment, which the agency considers the first gene therapy it has cleared to hit the market in the United States.
The treatment, called Kymriah, aims to give some patients a second chance after first-line drugs have failed. This may happen in up to a fifth of patients, according to the FDA.
Each dose of Kymriah contains a patients own immune cells, which are sent to a lab to be genetically modified using a virus. This therapy known as chimeric antigen receptor T-cell therapy, or CAR-T gives the cells the ability to recognize and kill the source of the cancer.
Were entering a new frontier in medical innovation with the ability to reprogram a patients own cells to attack a deadly cancer, FDA Commissioner Dr. Scott Gottlieb said in a statement.
Weve never seen anything like this before and I believe this therapy may become the new standard of care for this patient population, said Dr. Stephan Grupp, director of cancer immunotherapy at Childrens Hospital of Philadelphia, which spearheaded this research.
An FDA advisory committee had recommended the therapy for approval in July to treat the relapse of a blood cancer known as B-cell acute lymphoblastic leukemia, or ALL.
Based on available data, patients on the treatment have had an 89% chance of surviving at least six months and a 79% chance of surviving at least a year, with most being relapse-free at that point.
Almost 5,000 people were diagnosed with ALL in 2014, according to the US Centers for Disease Control and Prevention. More than half were children and teens. ALL is the most common type of cancer among children, according to the National Cancer Institute.
Most patients with ALL recover through other treatments such as radiation, chemotherapy and stem cells. But if the cancer recurs, the prognosis is poor.
There has been an urgent need for novel treatment options that improve outcomes for patients with relapsed or refractory B-cell precursor ALL, Novartis, the drug company that makes Kymriah, said in a statement.
Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease, Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said in a statement.
The one-time treatment has a boxed warning for cytokine release syndrome or CRS, a life-threatening side effect that can cause blood pressure to drop dangerously low. It is caused by overactive genetically modified immune cells. The FDA said hospitals and clinics must become certified to distribute the treatment, meaning they are prepared to recognize and treat CRS and other potentially fatal neurological events. Novartis said it hopes to have an initial network of 20 treatment centers within a month with plans to expand that to 32 by the end of the year.
Kymriah has a $475,000 price tag; however, patients who do not respond within a month of treatment will not be charged, according to Novartis.
Novartis is collaborating with (Centers for Medicaid Services) to make an outcomes-based approach available to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month. Future potential indications would be reviewed for the most relevant outcomes-based approach, the drug company said in a statement.
On Wednesday, the FDA also expanded approval for another drug, tocilizumab, to treat CRS in patients 2 and older.
In the main study that informed the advisory committees decision in July, roughly half of 68 patients experienced high-grade CRS, though none died from it. Slightly fewer patients experienced neurological events, such as seizures and hallucinations.
Novartis is required to conduct followup study to assess the safety of the treatment long-term.
CNN Wire and the CNN Video Affiliate Network is an online syndication service providing text and video versions of CNN's award-winning news coverage. Articles featured include reporting on world news, politics, finance, health, entertainment and technology.
See the rest here:
FDA announces first US gene therapy approval for cancer treatment - East Idaho News
- North Idaho resident working on a second chance at life - KREM.com - October 13th, 2022
- The Right-Wing Attempt to Control Higher Ed - The Chronicle of Higher Education - October 13th, 2022
- Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell Universal Donor Stem Cell for COVID-19 ARDS... - July 19th, 2022
- Hayden resident family determined to keep the fight against multiple sclerosis at home - KREM.com - July 19th, 2022
- Not Smart But Clever? The Return of 'Dumbphones' - WhoWhatWhy - March 25th, 2022
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 18th, 2021
- Bodybuilder, 47, looks half his age & claims the trick to his youthful appearance & strength is thinking h... - The US Sun - July 21st, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 29th, 2021
- Therapeutic Solutions International Uses StemVacs Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells - PRNewswire - February 23rd, 2021
- What Nutritionists Need You to Know About Smoke Point and Cooking Oils - msnNOW - October 8th, 2020
- CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |... - June 4th, 2020
- Dr. Dori Borjesson named dean of the WSU College of Veterinary Medicine - WSU News - January 25th, 2020
- In Utah, 'saving lives' with breast milk - FRANCE 24 - January 25th, 2020
- Oak Bay's top stories of 2019 - BCLocalNews - January 6th, 2020
- Robotics Industry Insights - Cobots, Raising the Human... - Robotics Online - Robotics Online - December 17th, 2019
- 100 hospitals and health systems with great orthopedic programs | 2019 - Becker's Hospital Review - December 7th, 2019
- Stem Cell Injections Shoulder | Cost of Stem Cell Therapy ... - September 10th, 2019
- News Releases - University of Idaho - May 16th, 2019
- Amniotic Stem Cell Injections, Advanced Muscle Integration ... - August 3rd, 2018
- Stem Cell Treatment Idaho | Stem Cell Treatment Sun Valley ... - September 21st, 2017
- Continuing the debate about right-to-die issues in Appleton - Idaho Statesman - September 4th, 2017
- Idaho National Laboratory - Wikipedia - November 30th, 2016
- Stem Cell Therapy | Stem Cell Treatments | Idaho Falls ... - August 5th, 2016
- Stem cell clinics, FDA, and giant, unapproved for-profit ... - November 1st, 2015
- SlidePlayer - Upload and Share your PowerPoint presentations - November 1st, 2015
- Stem Cell Therapy For Treating Canine Osteoarthritis | The ... - October 19th, 2015
- Umbilical Cord Blood Stem Cells | CancerConnect News - October 1st, 2015
- Brain Facts - Dialogue for Kids (Idaho Public Television) - September 27th, 2015
- Stem Cells | Cornerstone Family Council - July 2nd, 2015
- PPT Stem Cell PowerPoint presentation | free to view ... - May 2nd, 2015
- Stem Cells - The ALS Association - January 17th, 2015
- Stem Cell Therapy For Autism In USA - World Stem Cells, LLC - December 12th, 2014
- COPD Stem Cell Treatment | Analytical Stem Cell - December 2nd, 2014
- Cancer stem cell - Wikipedia, the free encyclopedia - August 23rd, 2014
- Stem Cells and the Future of Regenerative Medicine - August 23rd, 2014
- Idaho Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014